Home・Lista de Ações・Lantheus Holdings Inc

Lantheus Holdings Inc

Fechado

SetorSaúde

100.99 0.58

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

99.64

Máximo

100.77

Indicadores-chave
By Trading Economics
Rendimento	75M 193M
Vendas	11M 388M
P/E Médio do Setor	24.141 57.371
EPS	1.32
Margem de lucro	49.834
Funcionários	1,193
EBITDA	-69M 115M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+5.43% upside

Dividendos
By Acuity
Próximos Ganhos	5 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-1.4M 6.6B
Abertura anterior	100.41
Fecho anterior	100.99

Sentimento de Notícias

By Acuity

31%

69%

99 / 340 Ranking em Healthcare

Lantheus Holdings Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de ago. de 2026, 19:36 UTC

Lantheus Holdings Inc. shares are lower, impacted by a decline in the Health Care Supplies sub-sector. The asset remains near its one-month range low.

19 de ago. de 2026, 23:26 UTC

Lantheus Holdings Inc. is seeing modest gains in after-market trading, with no specific news identified to explain the price movement.

13 de ago. de 2026, 20:06 UTC

Lantheus Holdings Inc. is moving higher amid overall market gains, despite no specific company news to explain the advance.

12 de ago. de 2026, 23:36 UTC

Lantheus Holdings Inc. shares declined in after-market trading, remaining below their 20-day moving average amid recent inflation data influencing investor sentiment.

3 de ago. de 2026, 19:56 UTC

Social Media

News

Event

Lantheus Holdings Inc. to be acquired by Curium for up to $8 billion, offering $102.50 per share plus contingent value rights. Shares rise amid merger news.

31 de jul. de 2026, 22:01 UTC

Lantheus Holdings Inc shares are lower in after-market hours amid weak trading conditions, remaining below the 20-day moving average and near a one-month low.

30 de jul. de 2026, 17:31 UTC

Lantheus Holdings Inc is higher during Thursday's session, driven by overall market momentum, despite earlier downward pressure. The S&P 500 Index is also advancing.

29 de jul. de 2026, 21:42 UTC

Lantheus Holdings Inc is trading lower in after-market hours, influenced by a decline in the broader market and rising oil prices amid geopolitical tensions.

28 de jul. de 2026, 19:42 UTC

Social Media

Lantheus Holdings is in talks for a $7 billion acquisition by Curium, with shares declining despite the news and reaching a session low earlier.

27 de jul. de 2026, 22:51 UTC

News

Lantheus Holdings is in talks for a $7 billion acquisition of Curium. Shares are trading lower in after-market hours amid deal evaluations.

24 de jul. de 2026, 22:01 UTC

Lantheus Holdings Inc is trading lower in after-market hours, moving toward the lower end of its one-month trading range. No specific news was identified.

23 de jul. de 2026, 23:02 UTC

Lantheus Holdings Inc. shares are lower in after-market trading, continuing a downward trend since Thursday's close, remaining below the 20-day moving average.

22 de jul. de 2026, 19:06 UTC

Lantheus Holdings Inc shares are lower today, continuing a decline since Tuesday's close. Broader market sentiment is impacted by rising crude oil prices.

21 de jul. de 2026, 22:46 UTC

Lantheus Holdings Inc shares are trading higher in after-market hours, supported by a broader market rebound, particularly in the tech sector.

20 de jul. de 2026, 19:46 UTC

Lantheus Holdings Inc. shares are lower today, declining amid rising oil prices above $90 per barrel, contributing to inflationary pressures globally.

Comparação entre Pares

Variação de preço

Lantheus Holdings Inc Previsão

Preço-alvo

By TipRanks

5.43% parte superior

Previsão para 12 meses

Média 105.4 USD 5.43%

Máximo 115 USD

Mínimo 102.5 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Lantheus Holdings Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

10 ratings

Comprar

Manter

Vender

Com base em 10 analistas que deram avaliações de ações para Lantheus Holdings Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

99 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.